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ABSTRACT
Pharmacogenomics and pharmacogenetics play important roles in understanding 
how genetic variants influence drug efficacy and toxicity.  In cancer cases, both 
efficacy and toxicity of therapeutic agents determine the improvement of patient’s 
survival and quality of life. Effective treatment of cancer, one of the most deadly 
diseases in the world, is important to extend patient survival. Genetic variation 
influences the response of an individual to drug treatments in terms of efficacy 
and toxicity of the drugs. Understanding individual genetic variation is potential to 
achieve safer and more effective therapy, by tailoring drug options and dosage for 
each patient. In the context of cancer, tumors may have specific disease-defining 
mutations, but a patient’s germline genetic variation will also affect drug response. 
Advance research technologies approach such as GWAS, next-generation 
sequencing technologies, statistical genetics analysis methods, and clinical trial 
designs have shown promises for the discovery of genetic variants associated 
to drug response in cancer. Understanding the molecular characteristics of both 
tumor and patient, and establishing their relations to therapy outcomes would 
be critical for the identification of predictive biomarkers as well as providing the 
basis for individualized treatments. Since cancer is also frequent in Indonesia, 
pharmacogenomics study in oncology and its implementation in the clinical 
practice become important. Broad collaboration at national and international level 
could foster the application of personalized medicine in oncology.
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